

WHAT IF LESS MEANS MORE?



SPARK

SPARK by NCIS is published by the National University Cancer Institute, Singapore (NCIS).

5 Lower Kent Ridge Road,
Singapore 119074

Please address comments to
ncis_comms@nuhs.edu.sg

 (65) 6773 7888

 appointment@nuhs.edu.sg

 www.ncis.com.sg

 National University Cancer
Institute, Singapore

 [ncis.nuhs](https://www.instagram.com/ncis.nuhs)

 National University Cancer
Institute, Singapore

 [NCIS_NUHS](https://twitter.com/NCIS_NUHS)

 [NCIS NUHS](https://www.youtube.com/NCIS_NUHS)

Publish Date: June 2026

Copyright © is held by the
publishers. All rights reserved.
Reproduction in whole or in
parts without permission is
strictly not allowed.

Opinions expressed in SPARK by NCIS
are those of the writers and are not
necessarily endorsed by the National
University Hospital (NUH), National
University Health System (NUHS) and
their related companies. They are not
responsible or liable for the content of
any advertisements, articles,
photographs or illustrations contained
in this publication. No part of this
publication may be reproduced without
prior written permission of the NCIS.

IN THIS ISSUE

3 Executive Director's Note

4 About NCIS

6 Services at NCIS

Care for Our Patients

8 What if Less Means More?

14 Community Highlights

16 Balancing Precision with Compassion

19 When Memories Fade, Love Remains

Care for Our People

22 From Clinic to Classroom

28 Lighting the First Spark

31 Charting New Paths in
Oncology Pharmacy

Create Our Future

34 Operating for Tomorrow

38 Drug Combo Brings Hope
to NPC Patients

Ensure Sustainability

39 Extending Support beyond Our Clinics

41 Strengthening Our Fight against Cancer

43 Specialist and Cancer Programme
Listing



NCIS CANCER FUND

Make A Difference Today

Scan the QR code to support
the NCIS Cancer Fund

Executive Director's Note

At the National University Cancer Institute, Singapore (NCIS), our work is guided by a shared purpose: to deliver Incredible Care by setting new standards in cancer care. In this issue, we share stories that reflect how this is brought to life across different roles and disciplines.

We begin with a closer look at our Appropriate Care at End-of-Life (AptEOL) initiative, which focuses on aligning care closely with the needs of our terminally ill patients. By combining evidence-based practice with compassion, we show how doing less can mean giving more — more comfort, more dignity, and more space for what truly matters at the end of life.

Putting our patients at the heart of everything we do extends across every stage of the cancer journey. In surgical oncology, Adj A/Prof Vincent Nga shares how precision in the operating theatre is complemented by empathy, teamwork, and communication. On the research front, a clinical trial led by Prof Goh Boon Cher and Dr Chong Wan Qin exploring a combination of targeted therapies for advanced nasopharyngeal cancer offers new possibilities to improve cancer treatment through innovation. We also feature our Wellbeing Centre, which supports patients and caregivers through a range of thoughtful programmes and services.

As healthcare continues to evolve, education and continuous learning remain our key priorities. The desire to grow and develop is reflected in two of our nurses who are pursuing further studies, as well as in Dr Ivy Ng, the first recipient of our NCIS Spark Award. Their journeys highlight our ongoing efforts to equip our people with the right skills to thrive and succeed.

We hope this issue offers an inspiring look at how we are shaping cancer care in NCIS. Through these stories, we also celebrate the dedication, compassion, and collaboration that we bring to make a difference in the lives of those we serve.

With best wishes,

Cheng Ean

Adj A/Prof Chee Cheng Ean
Executive Director, NCIS



About NCIS

The National University Cancer Institute, Singapore (NCIS) is a national specialist centre under the National University Health System (NUHS). It is the only public cancer centre in Singapore that treats both paediatric and adult cancers in one facility.

With a broad spectrum of cancer care and management from screening, diagnosis and treatment, to rehabilitation, palliative and long-term care, NCIS' strength lies in the multi-disciplinary approach taken by our clinician-scientists and clinician-investigators to develop a comprehensive and personalised plan for each cancer patient.

We are guided by the following vision, mission and belief in our everyday work.

Vision: To be a world-leading comprehensive cancer centre, dedicated to the prevention, management and cure of cancer.

Mission: To deliver Incredible Care by setting new standards in cancer care.

Belief: Every person matters.



Cancer Programmes

Blood Cancers

Brain and Spine Cancers

Breast Cancer

Colorectal Cancer

Genitourinary Cancer

Geriatric Haematology-Oncology

Gynaecologic Cancer

Head, Neck and Thyroid Cancers

Hepato-Pancreato-Biliary (HPB) Cancer

Lung/Thoracic Cancer

Musculoskeletal Cancer/ Sarcoma

Paediatric Haematology-Oncology

Skin Cancer

Upper Gastrointestinal Cancer

Immune-Related Toxicity

Clinical Services

Ambulatory Services

Brachytherapy

Cancer Genetics

Cancer Imaging

Cancer Surgery

Cancer Survivorship

Cardio-Oncology

Clinical Trials

Geriatric Haematology-Oncology

Haematology

Immune-Related Toxicity

Integrative Oncology

Interventional Oncology

Medical Oncology

Medical Social Work

Molecular Tumor Board

Multidisciplinary Tumor Boards

Music Therapy

NCIS@Home

NCIS-On-The-Go

Nuclear Medicine

Nutrition

Occupational Therapy

Oncology Massage

Oncology Nursing

Oncology Pharmacy

Oncology Transplant

Ophthalmic Oncology

Palliative Care

Pathology

Patient Support Services

Physiotherapy

Proton Therapy

Psycho-Social Oncology

Radiation Therapy

Rehabilitation Medicine

Return to Work Program

Speech Therapy

Stem Cell and Cell Therapy

Stoma Therapy

Telehealth

Transplant Oncology



Services at NCIS

National University Cancer Institute, Singapore

- NCIS Chemotherapy Centre
- NCIS Radiotherapy Centre
- NCIS Cellular Therapy Centre
- Haematology-Oncology Research Group (HORG)
- NCIS Specialised Programmes

- NCIS Cancer & Blood Clinic @ Ng Teng Fong General Hospital (NTFGH)
- NCIS Radiotherapy Clinic @ NTFGH
- Palliative Care Services at Alexandra Hospital

- NCIS Radiotherapy Centre @ Tan Tock Seng Hospital
- NCIS Radiotherapy Clinic @ Khoo Teck Puat Hospital
- NCIS Radiation Oncology Clinic @ Woodlands Health Campus

- NCIS On The Go @ Pioneer
- NCIS On The Go @ Keat Hong
- NCIS On The Go @ Clementi

- NCIS Stem Cell & Cellular Therapy Hub @ 138 Depot Road



Pioneer Polyclinic



**Keat Hong Family
Medicine Clinic**



**Ng Teng Fong
General Hospital**



**Frontier Family
Medicine Clinic
at Clementi**



**Nat
Ca**







What if Less Means More?

Launched in October 2024, NUH's Appropriate Care at End-of-Life (AptEOL) initiative is reshaping care for cancer patients in their final months by focusing on what truly matters. Through the perspectives of a pharmacist, nurse, and programme manager, this story shows how thoughtful restraint — guided by evidence and compassion — can ease burdens, preserve dignity, and create space for more meaningful moments at life's end.



“I often ask myself if certain medications or interventions would truly help these patients.”

expectancy of more than 2.5 years. This is approximately the time needed to prevent one major adverse cardiovascular event (MACE). For patients who are not expected to live beyond six months, statins offer low benefit.

Continuing them, Ao Ran explains, can add to the treatment burden.

The same applies to vitamins and other supplements. At the end-of-life, some patients are no longer able to swallow safely. Others may feel overwhelmed by the sheer volume of drugs accumulated over years of chronic disease management.

“There was a patient I spoke with who demonstrated excellent knowledge of his medications,” Ao Ran recalls. “But at the end of our conversation, he quietly told me that the number of tablets had become too much.”

For Senior Clinical Pharmacist Boo Ao Ran, caring for patients at the end-of-life is all about prioritising their comfort and dignity.

It is a principle that guides her work in NUH’s Appropriate Care at End-of-Life (AptEOL) initiative, where pharmacists, clinicians, and nurses collaborate to ensure that every intervention serves a clear purpose in a patient’s final months.

A key part of her role is to carefully review each patient’s medications and stop those that no longer provide meaningful benefit, a process known as deprescribing.

For patients with a limited prognosis, some medications, such as those intended to prevent disease years down the line, offer little value. Take statins, for instance.

Based on existing research, statins show benefit mainly in individuals with a life

Recognising his distress, Ao Ran and her team conducted a thorough review of his medications and removed the non-essential drugs using the OncPal guideline developed under the programme. The guideline helps them pinpoint low-value regimens and provide evidence-based recommendations to prescribing doctors, who make the final decisions.

The impact was immediate. The patient expressed relief, knowing his care plan was now better aligned.

Not about giving up

Deprescribing is rarely just a clinical decision. For families, it can feel deeply emotional.

“Some of them were hesitant as it can be perceived as withdrawing treatment and their loved one might receive less care than they deserve,” Ao Ran explains.

In these situations, she and the team slowed the pace of discussions. They listened, acknowledged fears and explained that deprescribing was not about doing less, but about doing what mattered most.



Impact felt across system

While deprescribing increases pharmacists' workload through intensive medication reviews and detailed discussions with clinical teams and families, the downstream impact is significant.

An average of 3.3 medications were deprescribed for patients involved in this initiative, with 76% having at least one medication stopped. Some had up to 13 removed.

Reducing even one medication decreases dispensing, checking, packing, and material use. Across a large cohort, these small shifts accumulate into meaningful operational efficiencies, cost savings, and environmental gains that scale over time.

A life-changing experience

Working with patients at the end of life reminds Ao Ran of how fragile life is.

“Witnessing how families demonstrate resilience, love and unity during their most difficult moments is profoundly moving.”

When Ao Ran navigates complex decisions, she asks herself two questions: Would I want the medication continued if this was my family member? Would the intervention truly make a difference?

“If the answer is no, then the difficult conversations and careful reviews are worth it. Even a small act, such as discontinuing non-essential medication, can enhance a patient's final chapter.”

Benefits extend to bedside

The AptEOL initiative has also improved the care that patients receive from our NCIS nurses in the wards.

Wang Yanjun, Assistant Nurse Clinician, notes that some patients had up to 81 fewer episodes of vital signs monitoring and 27 days of intake and output charting. This meant more undisturbed rest throughout the night.

Patients were also spared dozens of finger-prick blood glucose tests, reducing the discomfort that could potentially arise from such procedures.

Reduced workload, increased satisfaction

With fewer non-essential interventions, nurses spend more time managing symptoms, providing comfort and being present at the bedside.

This shift has had a noticeable effect on staff morale. “Our total nursing workload has reduced by 162.6 hours,” Yanjun says. “We are empowered to practise the kind of nursing we entered the profession for by being patient-centred, and free from the moral distress of providing futile care.”

**What is Appropriate Care?**

NUH's Appropriate Care movement is part of a wider National University Health System (NUHS) effort to deliver evidence-based, purposeful care centred on what truly matters to patients.

Anchored in the belief that more isn't necessarily better, the Appropriate Care initiative encourages both clinicians and patients to engage in open, thoughtful conversations that best aligns with patients' goals and clinical needs. This helps strengthen trust, enhance patient experience, and ensure responsible stewardship of resources.



“Many clinicians are invested in doing everything possible for their patients, so the idea of deprescribing or reducing vital sign monitoring can initially feel counterintuitive.”

screening checklist for nurses to identify patients who would benefit from a more comfort-focused approach. Besides the deprescribing guidelines developed by the team’s pharmacists, a practical framework to de-escalate unnecessary interventions was also put in place for nurses to refer to.

Equally important were the regular, safe touchpoints created for feedback and refinement. These conversations allowed concerns to be surfaced early, lessons to be shared, and the approach to be improved.

By putting patients at the heart of every decision, the AptEOL initiative shows that doing less can truly mean more — more comfort, more presence, and more cherished moments spent at the final stage of life.

The importance of managing change

Behind-the-scenes, introducing the AptEOL initiative did not come without its challenges. Internally, the team had to gain buy-in and support from clinicians across various disciplines.

Esther Lin, Principal Dietician from Alexandra Hospital (a member of NUHS) and the initiative’s Programme Manager, admits that it took time,

dialogue and shared evidence to ensure everyone was aligned in understanding that doing less at the end-of-life can bring more comfort to patients.

There was also some hesitancy around stopping long-standing preventive medications or reducing tests, as these practices were deeply embedded in routine care.

To bridge this, the AptEOL team developed a clear

Community Highlights

At NCIS, community outreach remains an important part of our work to advance cancer awareness, prevention, and support. In this issue, we look at two meaningful initiatives we were part of — Relay For Life and Breast Cancer Awareness Month — which brought together staff, patients, caregivers, and partners in support of education, advocacy, and survivorship.

Relay for Life 2025



From 8 to 9 March 2025, 46 clinicians, medical social workers, pharmacists, and operations and administrative staff took part in the Singapore Cancer Society – TalkMed Relay for Life to rally support for cancer patients, survivors, and their families.


Competing in the 100KM Challenge, our colleagues ran a remarkable 163.6km overnight, surpassing the previous year's record of 148.7km. Their determination and teamwork secured an overall placing of 9th out of 183 teams, marking another milestone achievement for NCIS at this national event.

Through the physical challenge, Team NCIS also raised \$13,656 to support cancer care and advocacy efforts. This was made possible through the generosity and encouragement of staff, donors, and supporters who stood alongside the team throughout the night.

Relay For Life 2025 once again reflected the NCIS spirit of unity, resilience, and partnership with the wider community — reinforcing our commitment to stand with cancer patients at every stage of their journey.

163.6KM

COVERED



Breast Cancer Awareness Month 2025: Celebrate Her Strengths



In October 2025, NCIS marked Breast Cancer Awareness Month (BCAM) with a series of public engagement and community initiatives aimed at raising awareness, encouraging early detection, and strengthening support for those affected by breast cancer.

Anchored on the theme “Celebrate Her Strengths”, the month-long campaign also featured an in-house documentary honouring five of our breast cancer survivors. Titled “Frames of Her Strength”, the film captured the challenges and triumphs these women

experienced across different seasons of life, highlighting both their vulnerability and resilience throughout their cancer journeys.

NCIS also collaborated with various partners, such as TOMORO Coffee, Burnt Cones, and Simple Wellness to further extend the reach and impact of its campaign. These partnerships enabled members of the public to support the cause through everyday lifestyle choices, such as purchasing special pink-themed offerings. Proceeds from these products were channeled towards the NCIS Cancer Fund.

Through its multi-faceted approach, BCAM 2025 reinforced NCIS’ role as a healthcare institution deeply connected to the community it serves.




Hannah Seow (left) discovered she had breast cancer after a self-examination in 2023. Scan the QR code to hear her story, along with those of four other cancer survivors, in Frames of Her Strength.



Balancing Precision with Compassion

Surgical oncology demands precision, but compassion is just as critical. Just ask Adj A/Prof Vincent Nga, who believes that truly incredible care means seeing the patient beyond the diagnosis. In this interview, he shares how empathy, teamwork, and personal connection shape every decision he makes in and out of the operating theatre.



What got you into surgical oncology?

The greatest joy for me is seeing the smiles on patients' and caregivers' faces after a successful brain or spine tumour surgery. It is an extraordinary privilege to walk alongside patients during one of the most difficult journeys of their lives. That privilege — to restore hope and quality of life through surgery — is what drew me to surgical oncology and continues to inspire me every single day.

How do you collaborate effectively across disciplines to ensure that patients receive seamless care?

Collaboration is at the heart of modern brain tumour care. Open discussions — both formal, through multidisciplinary tumour boards, and informal, through day-to-day conversations — are vital. To further improve seamless care, we established a multidisciplinary paediatric brain tumour clinic in 2021, and are extending this model

to our adult patients. With core specialists co-located in the same clinic, patients receive truly integrated care. This reduces miscommunication and ensures that every decision is aligned, timely, and centered on the patient.

Share with us your most memorable experience with a patient.

A 90-year-old lady with a suspected aggressive glioblastoma multiforme. My role was limited to performing a minimally invasive robotic-assisted biopsy to confirm the diagnosis. Yet what stayed with me was her immense gratitude, and the sense of peace and joy she showed during our ward rounds. I was deeply moved when her family shared that she genuinely looked forward to her post-discharge clinic visits because she felt cared for and loved by the healthcare team. Her grace and strength were humbling, reminding me that healing goes far beyond the operating theatre.



Part of the brain cancer team in NCIS includes Adj A/Prof Bala Vellayappan from Radiation Oncology (2nd from right) and Dr Yvonne Ang (3rd from right) from Medical Oncology. The team works closely together to deliver dedicated clinical research, expertise and care for our patients.

It is stated in your biosketch that you believe it is important to care for patients as individuals first. How is this belief brought across in the way you treat your patients?

Every patient is unique, and so their care must be as well. From the simplest details, like whether the preference is for minimal hair shaving or a full head shave, to the most complex surgical decisions, I make it a point whenever feasible to honour patients' preferences. Sometimes this may mean choosing to leave part of a tumour behind to minimise the risk of neurological deficits, and other times pushing for maximal tumour removal to give the best chance of long-term tumour control. For me, treating patients as individuals means balancing medical goals with what matters most to them as people.

Before entering the operating theatre, what's a habit or ritual that you do?

Before every surgery, I take a moment for a quick prayer, then mentally rehearse each step of the procedure in detail. I think through possible scenarios — both expected and unexpected — and how I might respond. This preparation grounds me and ensures that I am as ready as possible, though surgery will always challenge us with the unknowns. In those moments, we rely on our experience, our team, and our presence of mind to do what is best for the patient.

What's the longest surgery you have performed, and how do you maintain your focus during that procedure?

One of the most demanding cases I recall recently was an 8-hour surgery on a six-year-old child with a large brain tumour occupying nearly a quarter of his head. The tumour's location and hard consistency meant we had to work with extreme precision to avoid injury to critical blood vessels and neural structures. Mental and physical conditioning


are essential, but so is teamwork. Having skilled assistants and, at times, co-surgeons allow me to stay focused and take short breaks when needed. Ultimately, it is the adrenaline and sense of purpose that sustain me through those long hours.

What continues to inspire you to push new frontiers in surgical oncology?

My greatest inspiration comes from my patients. Their courage motivates me to constantly seek ways to make brain surgery safer, more effective, and less invasive. Beyond the operating theatre, I am energised by our research collaborations with scientist colleagues at NUS and Institute of Molecular and Cell Biology (IMCB), where we are constantly working to discover new therapies for some of the most challenging brain tumours. The hope that one day we can offer patients more effective treatments drives me to push the frontiers.



Adj A/Prof Nga also leads the development of high-impact educational programs and masterclasses, such as the International Surgical Oncology Symposium (ISOS), which brings together leading experts from around the world to exchange insights.



When Memories Fade, Love Remains

In this moving account of one of Adj A/Prof Vincent Nga's patients, we hear more about what it means to slowly lose what once felt certain — and the quiet strength found in love and support along the way.

“I want my old Papa back.”

James Ong remembers very little of the most critical period of his illness. Nearly two months — just before and after his brain surgeries — are missing from his memory. What remains is a quiet sense of having been carried through a time he could not navigate on his own.

Before the diagnosis, the changes were subtle. James seemed more tired. Less sharp. His wife, Siling, noticed growing signs — brain fog, short-term memory lapses, moments when he appeared lost. Trusting her instincts, she paid closer attention.

When James developed acute memory loss, Siling brought him to the A&E at National University Hospital (NUH). During the drive, she realised how much James had slipped away. He no longer knew what NUH was — an indication that he was deteriorating rapidly.

Within hours, the diagnosis came: a “mass” in his brain.

“I was grateful that I was not the only pair of eyes looking out for James,” Siling admits.

The next morning, they were linked with Adj A/Prof Vincent Nga and the neurosurgical team. The doctors were gentle but clear, surgery was urgent.



“How much time do we have?” Siling asked.

The operating theatre had already been booked. The team was ready. Once she gave consent for the operation, they were ready to proceed.

“So, in other words, I was the only one standing in the way,” she says.

The space between who he was and who he is

James underwent three surgeries during his time in NUH — first to relieve pressure in his brain, then to remove the tumour, and finally to insert a permanent shunt.

“Not everyone recovers well. Some have lingering disability because of the surgery,” James shares. “I was fortunate.”

Recovery, however, was not simple. James experienced profound short-term memory loss. At one point, he retained only about a minute of memory at a time. He knew he was a husband and a father of four, but physically, he presented as someone decades older.

For Siling, this period was marked by grief. “The difficulty was not knowing if the James I knew was still present. I see snippets of him that was still himself, but it was no longer the same.”

When James returned home, new challenges emerged. In the early months, headaches, pain, and extreme tiredness lingered. His children struggled to understand why he was suddenly short-tempered and seemingly unwilling to interact.

When his son said, “I want my old papa back,” James broke down.

He needed to hear it. And in hearing it, he grieved — both for himself and for what his children had lost. Over time, he and Siling spoke openly with them on what had happened and what healing would require.

Held by more than love alone

Much of the caregiving fell to Siling. She managed the home, supported their four children, and followed every medical update closely.

“She would often be the one who briefs the family of my condition. The doctors even asked if she was in the medical line because she was able to understand well everything that I was facing,” James says.

Siling wasn’t, but she listened, learned, and stayed present.

“When you get married, nobody ever thinks or wishes that their other half will fall sick or be in a life-threatening situation,” James reflects. “I’m thankful that she knows me so well that she noticed the differences in me and got me


the medical attention I needed.”

He calls her his cheerleader.

“Siling makes sure I take my pills, do my basic exercises and helped me overcome my difficult days. For that, I would like to thank her for everything she’s done for me.”

There are chapters of this journey James does not remember, but their impact is deeply felt.

Through loss, recovery and change, what endured was the commitment to show up — for each other, and for the life they continue to rebuild together.







From Clinic to Classroom

As healthcare rapidly evolves, two dedicated nurses from NCIS are stepping back into the classroom to advance their knowledge and skills. Motivated by a deep commitment to their patients and a desire to lead positive change, they are embracing new challenges to become catalysts for innovation and improvement within their respective fields.

Lim Chi Ching, Advanced Practice Nurse

Pursuing a PhD in Nursing at the National University of Singapore (NUS)

For Chi Ching, the decision to continue studying is driven by her commitment to provide better support for individuals with multiple myeloma.

“Although remission rates have improved, multiple myeloma remains an incurable type of blood cancer. I want to deepen my knowledge and contribute meaningfully to the lives of these patients,” she says.

Having been with NCIS for 16 years, Chi Ching brings a wealth of experience into the classroom. Yet, she is excited by the prospect of acquiring new skills, such as designing large-scale, high-impact research projects and applying different methodologies to her clinical practice.

“These will enhance my ability to provide evidence-based care, understand the needs of my patients better and improve my capacity to educate patients and colleagues about new treatments,” she adds.

Overcoming challenges

The PhD programme, which Chi Ching is

pursuing part-time over four years, requires her to be in school twice a week. Balancing these demands with her clinical role and family responsibilities has not been easy.

“There have been many late nights as I try to keep up with assignments while ensuring patient care remains uncompromised,” she admits.

The key, she explains, has been a strong support system. At work, she collaborates closely with her peers and fellow advanced practice nurses to ensure seamless coverage when she is away.

At home, her husband has taken on greater responsibilities, including caring for their daughter.

Chi Ching also highlights the guidance she received. Sister Seri Sastika, Head of Oncology Nursing, supported her Learning and Development Award and adjusted her work

schedule. Her faculty mentors, Dr Vivien Wu and Prof Wilson Tam, assisted in designing her research methodology, while thesis supervisors Dr Melissa Ooi and Prof Chng Wee Joo provided invaluable inputs for her research proposal and helped secure funding.

The most inspiring part of the PhD for Chi Ching so far has been her exposure to peers from around the world. Her cohort includes



students from data science, statistics and education.

“The diversity creates a rich, collaborative environment. We learn from each other’s strengths and see how different disciplines approach healthcare challenges,” she explains.

Shaping the future of oncology nursing

Looking back at her time in NCIS, Chi Ching describes the PhD as one of the most significant milestones in her career.

“This PhD is not just about personal growth. It reflects a commitment to advancing patient care and building capacity for nurse-led research,” she says.

Asked what advice she would give to her peers who are considering further education, Chi Ching was clear:

“Continuous learning is critical in healthcare. The challenges of furthering your studies are real, but so are the rewards. Align it with your passion, and surround yourself with the right support system.”

Once her PhD is complete,



Chi Ching hopes to support the development of NCIS’ Cancer Advocacy and Research (CARE) office, mentor other nurses in evidence-based quality

improvement and primary research, and contribute to both national and international guidelines in oncology nursing.

“I see oncology nursing becoming more patient-centred, more research-driven and more involved in shaping policies and practices. My hope is that nurses will play a bigger role in leading change and not just delivering care.”

Carol Ho, Advanced Practice Nurse

Pursuing a Doctor of Nursing Practice (DNP) programme at NUS

Carol was inspired to enrol in Singapore's first Doctor of Nursing Practice (DNP) programme after attending a cancer survivorship conference earlier this year.

Amid stories of resilience and recovery, she was moved by something less often discussed: the ongoing emotional, psychological, and social struggles many survivors with metastatic cancer face.

"Hearing their personal stories made me realise there is an urgent need to improve their care in Singapore," she shares.

That moment of clarity came at the right time. Around the same period, Carol attended a talk on the DNP programme by NUS and realised how closely it aligned with her aspirations.

Launched in August 2025, the two-year part-time programme is designed to equip students with the capabilities to transform healthcare systems, enhance patient outcomes and drive evidence-based practice.

With a focus on innovation, leadership, and interdisciplinary collaboration, the DNP programme prepares them to address complex healthcare challenges and lead system-wide improvements.

Carol was also drawn to the project-based components of the course, which let her turn ideas and research into practical solutions to improve patient care.

The path to change

Carol is one of seven Advanced Practice Nurses (APNs) in a cohort of 16 students. Being part of the pioneer batch has been both humbling and empowering, but not without its hurdles.

"There was a moment of self-doubt when someone questioned my suitability for the programme because of my age," she recalls. "But the unwavering support from senior leaders and mentors has been incredibly encouraging."

After completing the first few weeks of classes, Carol is more certain than ever



"I hope to foster an environment of continuous improvement and innovation within NCIS and beyond."

that age and experience are not barriers to effecting change. Younger nurses, after all, can bring fresher perspectives, energy and a readiness to challenge the status quo in pursuit of better clinical outcomes.

This drive to question and improve existing practices is exactly what the DNP programme fosters. By equipping students with the skills to translate evidence into practice, it addresses the long-standing 17-year gap between primary research and real-world implementation to drive sustainable, system-wide improvements at a much quicker pace.

Carol is already planning to put what she learns into practice back at NCIS. “I intend to utilise the skills acquired to address intricate healthcare system issues by integrating evidence-based practices into strategic decision-making and policy formulation,” she says.

Setting an example

Carol also aspires to grow as a transformational leader in Advanced Nursing Practice, mentoring younger nurses and contributing academically to the nursing community.



As Carol and her pioneering cohort forge new paths, they are redefining what nurses can achieve. In doing so, they ensure that patient care in

Singapore continues to evolve, improve, and meet the complex needs of today and tomorrow.

Differences between a DNP and a PhD in Nursing

The Doctor of Nursing Practice (DNP) focuses on clinical practice and leadership, preparing nurses for advanced patient care, system improvement, and healthcare management. Rather than conduct theoretical research, DNP graduates apply existing research to solve real-world problems in healthcare settings.

In contrast, a PhD in Nursing emphasises the generation of new knowledge through original research. Students are equipped with the skills to design and conduct independent studies, develop nursing theories, and contribute to academic and scientific advancements.

Lighting the First Spark



Dr Ivy Ng was the first NCIS staff to receive the NCIS Spark Award, an educational sponsorship programme, when it was launched last year. She shares more about her motivation to pursue further studies and her hopes for the future in this story.

For Dr Ivy Ng, teaching has always been a natural extension of her clinical practice.

A consultant in the Department of Radiation Oncology at NCIS, Dr Ng also serves as a Clinical Assistant Professor at NUS Yong Loo Lin School of

Medicine. There, she trains medical students in patient communication and supervises those doing their placement in radiation oncology.

But as her career progresses, Dr Ng is taking on responsibilities that extend beyond just that.

As Deputy Director of Education at NCIS and Training Network Director for the Royal Australian and New Zealand College of Radiologists (RANZCR), she is increasingly involved in shaping the systems, culture and policies that define how learning takes place.

Dr Ng's pivot towards education leadership led her to apply for the NCIS Spark Award. She is currently pursuing a Master of Health Professions Education programme at Monash University.

The Spark Award is NCIS' educational sponsorship programme. It is designed to recognise and support individuals with exceptional talent and dedication to advance the skills necessary for a rapidly evolving landscape in cancer research, diagnosis, and treatment.

With the upcoming transition of local radiation oncology training to a residency model, the Master of Health Professions Education programme will enhance Dr Ng's skillsets in curriculum and faculty development, assessment and feedback systems, as well as trainee wellbeing.

It will also equip her with the knowledge required to develop scalable oncology training frameworks for the region, and ensure that innovation and AI are introduced under proper supervision.

Dr Ng already sees several ways to apply what she learns in NCIS.

First, she hopes to strengthen curriculum design by moving towards intentional, competency-based training with clearer developmental milestones.

Second, she aims to support consultants with practical tools to teach effectively without increasing burnout.

Third, she plans to ensure more structured feedback and integrate AI in ways that

enhance, rather than replace, human supervision.

"Ultimately, my goal is to translate educational theory to improve both trainee experience and patient care," she says.

What makes an exceptional educator?

Having won the Great Teacher Award in 2024 and the Dean's Award for Teaching Excellence in 2023, Dr Ng believes that incredible educators do more than transfer knowledge.



“They see potential before it’s visible. They create psychological safety while maintaining high standards. They design and remove friction in the learning process.”

Finding the balance, Dr Ivy maintains, is delicate.

Excellence without compassion, she explains, breeds fear, while compassion without standards limits growth.

To prevent either from taking root, Dr Ng now places greater emphasis on deliberate practice, improving feedback literacy and inculcating a growth mindset.

“In many ways, the question has shifted from ‘How do I teach well?’ to ‘How do I build environments where others thrive?’,” she shares.

Strengthening NCIS as an Academic Medical Centre

With this in mind, Dr Ng feels that there are multiple opportunities to strengthen the organisation’s academic standing in ways that benefit both staff and partners.

This includes aligning education with research and clinical excellence to ensure that learning is evidence-based and directly relevant to patient care, while investing in structured faculty development to enhance teaching quality and help clinicians become more effective educators.

Dr Ng also hopes to further position Singapore as a regional hub for oncology education by expanding access to comprehensive training programmes, facilitating knowledge exchange across borders, and building stronger partnerships with other healthcare institutions in the region.

“An academic medical centre is defined not only by research output, but by how intentionally it develops people,” she says.

Encouraging growth

For anyone who is passionate about self-improvement but hesitant to take the next step, Dr Ng offers a simple piece of advice: just follow your curiosity.

“Further education is about sharpening how you think,” she adds. While it requires commitment, the investment

individuals make in their own learning can create a ripple effect on others.

As the first recipient of NCIS’ educational sponsorship award, Dr Ng has ignited a spark for others to follow and create an even greater impact on the lives of the people they serve.

What is the NCIS Spark Award?

Launched in 2025 as part of our talent development efforts, the NCIS Spark Award supports staff with exceptional talent to develop the critical skills necessary for a rapidly evolving landscape in cancer research, diagnosis and treatment.

By investing in their education and training, NCIS aims to foster an environment where innovation, compassion and expertise converge to address the complex challenges posed by cancer.

Charting New Paths in Oncology Pharmacy

Over the past 14 years, Constance Teo has built her career in oncology pharmacy, progressing from Pharmacist to Senior Principal Clinical Pharmacist and the Head of Department. We spoke with her to learn more about her journey, leadership insights and vision for the future.



You've been with oncology pharmacy for 14 years. What has kept you inspired all these years?

Oncology pharmacy is at the forefront of cancer therapy, with new treatments and clinical trials emerging regularly. There's never a lack of new things to learn. The multifaceted nature of our work continues to challenge and engage me. Over the years, what's kept me going is the sense of purpose — knowing that the work we do, whether directly with patients or behind the scenes, truly makes a difference in their treatment journeys.

What have been some of the most defining moments of your career?

Some of the most defining moments in my career have centered around pioneering innovative projects that have transformed patient care delivery at our institution. I was privileged to be given the opportunities to lead the establishment of the outpatient

EPOCH chemotherapy initiative and was involved in the set-up of NCIS-On-The-Go. Being part of the NCIS Right Siting Committee, where we continually work on optimizing processes to improve patient care, continues to be a very meaningful part of my career. Working alongside a passionate team of doctors, nurses, and operations colleagues, challenging the status quo and implementing changes that have a tangible impact on patient care, makes all these moments truly defining.

You took on the role as Head, Oncology Pharmacy in August 2024. What have been the top highlights of leading the team?

Three key highlights stand out: First, we've made significant strides in operational efficiency, including a notable \$3 million reduction in inventory costs in the past year. Second, we've begun reimagining future workflows to prepare for the upcoming compounding hub, ensuring we're ready for



the evolving landscape of cancer care. Lastly, we've also started focusing on creating new career paths and roles for our pharmacy technicians and assistants, fostering growth and development within our team.

Looking back at your career, is there a particular moment that has stuck with you and reminded you of why your work matters?

One experience that stood out involves a patient undergoing EPOCH chemotherapy. This patient was experiencing recurring leaks with their infusion pump, which caused significant distress and could potentially compromise treatment.

Together with the nursing team, I investigated the cause of the leakage and provided targeted patient education on proper pump management. Even though we had used the same infusion set up for several years, we explored a different infusion set. We used samples and did experiments with the new set, leaving it overnight to test for leakage and prevent similar occurrences in the future. This experience reinforced the importance of collaborative problem-solving and continuous improvement in oncology pharmacy, reminding me that we can always do better for our patients.

What are some of the biggest changes in oncology pharmacy since you began your career?

The scope of oncology pharmacy has expanded tremendously. Digital tools, immunotherapy, and value-based care have redefined how we practice, requiring us to be more adaptable and tech-savvy than ever.

What is one mantra you live by every day?

Progress, not perfection. One step at a time.

How do you see the role of pharmacists evolve in the future of cancer care?

Oncology pharmacists will be involved in tailoring treatments to individual patients' genetic profiles, optimising efficacy while minimising side effects. We will also contribute to shaping cost-effective treatment plans and leverage technology in medication management, drug interaction screening, AI-assisted patient counselling and education, and chemotherapy reviews. We will become even more integral members of the oncology care team, collaborating closely with physicians and other healthcare professionals to drive innovation and improve patient outcomes.

What's the legacy you look to leave behind in oncology pharmacy?

I hope to inspire my team to be empowered, resilient, and future-ready — one that champions innovation while never losing sight of empathy and patient-centric care.







Operating for Tomorrow

Prof Jimmy So has served as Head and Senior Consultant of the Division of Surgical Oncology at NCIS for the past seven years. We spoke with him to find out how he is driving innovation and education to improve patient outcomes today and shape tomorrow's cancer care.

The rhythmic thud of a ping pong ball echoes through the hall. At one end of the table, a man leans forward with ease, his grip firm on the paddle. Not long ago, gastric cancer had forced him into the operating theatre. After a complex laparoscopic gastrectomy, the once avid athlete has returned to his usual routine, now playing table tennis four times a week.

For Prof Jimmy So, Head of Surgical Oncology at NCIS, this story of his patient is a powerful reminder of the extraordinary resilience individuals with cancer demonstrate and the vital role medical care plays – not just in saving lives, but in helping people reclaim a sense of normalcy.

Yet, the path to such outcomes is evolving rapidly. While the scalpel remains central to Prof So's work, the future of cancer care and surgical oncology is being increasingly shaped by artificial intelligence (AI), education, and new procedures.

The promise of AI

AI, once seen as experimental, is now permeating into everyday clinical practice. "AI will be an important technology to

help clinicians treat cancer better," says Prof So. "For example, AI has enhanced the detection and quality assurance during an endoscopy to improve the accuracy of the diagnosis."

Another area AI assists in is decision-making. AskBob, a consultation and treatment tool Prof So co-developed with colleagues, analyses global clinical guidelines, meta-analyses and randomised controlled trials to offer personalised treatment recommendations. It also highlights supporting evidence-based literature that allows doctors to understand the rationale

behind each suggestion provided.

By putting such information at their fingertips, AskBob helps clinicians make decisions faster and with greater confidence. This will improve the quality of cancer treatment in Singapore and beyond.

Educating for excellence

Besides technology, education also forms the bedrock of progress. "The most urgent knowledge gap today is keeping surgeons up-to-date with the current management of cancer and surgical standards," Prof So says.



During one of the surgeries observed by the writers of this article, Prof So turned to two medical students and began quizzing them on the procedure — asking specific questions, testing their understanding of the steps involved, and offering corrections where necessary.

That's where platforms like the International Surgical Oncology Symposium (ISOS) come in. By becoming a hub for the global surgical oncology community, NCIS plays a vital role in advancing cancer care through the exchange of knowledge.

This commitment to learning is also embodied in Prof So's mentorship of younger surgeons. Having trained and guided many in the field, he continues to inspire the next generation by sharing his expertise, nurturing their development, and preparing them to become world-class.

Fueling fresh ideas

Prof So's drive towards excellence is backed by an environment that actively supports research and innovation. Being part of the National University Health System (NUHS), he and his team are uniquely positioned to turn ideas into impact. "Through seed funding from the institution and national grants, as well as the large ecosystem within NUS, we can readily pursue research in surgical oncology," he explains.

One such example is the extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL) trial, a large

study Prof So led involving five countries and 23 institutions.

The results were presented at the plenary session of the Gastrointestinal Symposium of American Society of Clinical Oncology (ASCO) and published in the *Lancet Gastroenterology and Hepatology* journal. In recognition of these contributions, Prof So received the peritoneal prize by the International Society for the Study of Peritoneum and Pleura (ISSPP).

New forms of treatment


Looking ahead, Prof So believes that new targeted therapies and minimally invasive surgeries will be key to transforming outcomes for gastric and oesophageal cancers.

When combined with AI-powered tools and a strong emphasis on ongoing education, these innovations promise a future where treatment is not only more precise but also helps patients regain healthier, fuller lives.

And if proof is needed, it is found in the man at the ping pong table, striking the ball again and again in a glimpse of what tomorrow's operating theater can make possible.



At the International Surgical Oncology Symposium (ISOS) in 2025, Prof So shared more about the future of surgical oncology and integrating precision medicine into clinical trials.



Drug Combo Brings Hope to NPC Patients

A randomised clinical trial in Singapore led by Prof Goh Boon Cher and Dr Chong Wan Qin to use a combination of two targeted therapies — pembrolizumab and bevacizumab — is showing promise for patients with advanced platinum-resistant nasopharyngeal cancer (NPC).

The clinical trial involved 48 patients with platinum-resistant NPC. Half of them received pembrolizumab alone, while the others received both pembrolizumab and bevacizumab.

Tumours shrank in 58% of patients who got the drug combo, compared to just 13% of those who received pembrolizumab alone. Patients who were given both drugs were also able to keep their cancer from worsening for about 14 months on average,

compared to just 1.6 months for those who were on pembrolizumab alone.

Analysis of the tumour samples obtained from the patients on this trial revealed bevacizumab enhanced immune cells infiltration into the tumour to perpetuate an immune active milieu for pembrolizumab to induce an anti-tumour response.

If validated in a phase 3 trial, the combination therapy could set a new standard of care for these patients.

What is NPC?

Nasopharyngeal carcinoma (NPC) begins at the back of the nose in an area called the nasopharynx (circled above). The standard treatment usually involves chemotherapy with platinum-based drugs. However, in some patients, the cancer returns or spreads, causing a condition known as platinum-resistant NPC.

When this happens, doctors may turn to other treatments such as pembrolizumab, a form of immunotherapy that works by helping the immune system recognise and attack cancer cells.

Extending Support Beyond Our Clinics

The new NCIS Wellbeing Centre offers holistic support to patients and caregivers by fostering comfort, meaningful connection, and a sense of calm. Through a range of thoughtful programmes and services, the centre complements clinical care and helps individuals navigate the cancer journey with greater resilience and confidence.





They can also find moments of joy in music by playing the piano, generously donated by NUHS Board Member Ms Tracey Woon, or listening to performances from volunteers.

Meanwhile, the Tree of Life, decorated with handwritten messages of encouragement from patients, families, and staff stands as a reminder of the power of shared strength and resilience.

Uniting the community

Since its opening, the NCIS Wellbeing Centre has brought both patients and caregivers together through a number of thoughtfully arranged activities.

These include calligraphy workshops, stretching and breathing classes, as well as supportive conversations with medical social workers and nurses.

With this space, visitors can look forward to more shared moments of respite as we strive to ensure holistic, person-centred care.

Visit for.sg/ncispwp to know about the latest events that will be held at the Wellbeing Centre.

Tucked away on Level 8 of NUH's Medical Centre lies a sanctuary of care designed to enhance our support to patients and caregivers.

Launched on 19 June 2025, the NCIS Wellbeing Centre underscores NCIS' belief that true care extends beyond medical treatment and encompasses an individual's mental and emotional state.

The centre offers a quiet, welcoming space that brings calm and reassurance. Thoughtful touches — from warm lighting, comfortable seating and a cosy pantry with complimentary drinks to shelves of books and board games — provide

simple moments of comfort, while symbolic features invite reflection and bring deeper meaning.

Patients can ring the Bell of Hope to celebrate the end of treatment and the beginning of a new chapter.



Strengthening Our Fight against Cancer

NCIS continues to drive collaboration and shape the future of cancer care in Singapore and beyond through various partnerships and educational platforms. In this issue, we take a closer look at the annual International Surgical Oncology Symposium (ISOS) and NCIS Annual Research Meeting (NCAM) held last year which brought clinicians, researchers, and healthcare professionals together to exchange insights and advance innovation in oncology.

International Surgical Oncology Symposium (ISOS)

Held on 27 Sep 2025, the fourth International Surgical Oncology Symposium (ISOS) was attended by a distinguished panel of international and local experts who exchanged insights on cancer surgery and patient-centred care.

Centred on the theme Education and Innovation in Surgical Oncology – Bridging Knowledge for Better, the one-day event explored emerging technologies, evidence-based approaches, and the growing role of data-driven innovation in enhancing clinical decision-making and outcomes through three scientific tracks — Precision Medicine, Innovation and Artificial Intelligence, and Advances in Surgical Oncology.

With strong faculty representation and a vibrant exchange of ideas, ISOS 2025 strengthened professional networks and reinforced its role as a leading platform for knowledge sharing.



Among the distinguished speakers at ISOS 2025 was Prof Leah Backhus, a thoracic surgeon from the United States who practises at Stanford Hospital and serves as Chief of Thoracic Surgery at the VA Palo Alto Health Care System. During the symposium, she shared more about the topic: "Transitioning from Video-Assisted Thoracic Surgery (VATS) to Robotic Thoracic Surgery".

NCIS Annual Research Meeting (NCAM)



Guided by the principle that “An Ounce of Prevention is Worth a Pound of Cure”, NCAM 2025 focused on bridging the gap between research and clinical practice to advance the science of early cancer detection and prevention.

Various distinguished speakers took to the stage to share their expertise in this area. Among them was A/Prof Mikael Hartman from NUH’s Division of General Surgery (Breast Surgery), who presented on “Tailoring Screening for Risk in Breast Cancer Prevention”, and Prof Lee Soo Chin from the Department of Haematology-Oncology who shared more about the insights gathered from a large-scale screening mammography uptake study.

Meanwhile, Prof Dennis Lo (pictured), internationally renowned for his groundbreaking work in liquid biopsy, delivered the plenary session on “New Frontiers for Cancer Detection using Cell-Free DNA”.

NCAM 2025 received an impressive 125 abstract submissions across six categories: Basic Science, Translational Science, Clinical Science, Nursing/Paramedical/Supportive Care, Digital Health and Quality Improvement.

44 submissions were selected for oral and poster presentations, with 24 awards presented to recognise outstanding contributions to cancer research and care.

Specialist and Cancer Programme Listing

Blood Cancers

Chair

Dr Melissa Ooi

Bone Marrow and Stem Cell Transplant Programme

Haematology

Adj A/Prof Michelle Poon (Lead)
A/Prof Koh Liang Piu
Dr Esther Chan
Dr Tan Lip Kun
Dr Edwin Thong
Dr Victor Ling

Multiple Myeloma

Haematology

Prof Chng Wee Joo (Lead)
Dr Melissa Ooi
Dr Sanjay De Mel
Dr Cinnie Yentia Soekojo

Radiation Oncology

Adj A/Prof Bala Vellayappan
Dr Wong Lea Choung
Dr Lee Shing Fung
Dr Yip Pui Lam

Lymphoma

Haematology

Adj A/Prof Michelle Poon (Lead)
Adj A/Prof Chee Yen Lin
Dr Anand D Jeyasekharan
Dr Esther Chan
Dr Sanjay De Mel
Dr Tan Lip Kun
Dr Sim Hau Wui
Dr William Chan

Radiation Oncology

Adj A/Prof Bala Vellayappan
Dr Wong Lea Choung
Dr Lee Shing Fung
Dr Yip Pui Lam

Pathology

A/Prof Ng Siok Bian
A/Prof Tan Soo Yong
Dr Gareth Turner
Dr Susan Hue
Dr Wang Shi

Thrombosis & Haemostasis

Haematology

Adj A/Prof Chee Yen Lin [Lead]
Adj A/Prof Yap Eng Soo
Dr Lee Shir Ying
Dr Cheryl Lim
Dr Stephrene Chan
Dr Winnie Teo
Dr Eunice Lai
Dr Maggie Wong

General Haematology

Haematology

Dr Lee Shir Ying
Dr Liu Te Chih
Dr Tan Lip Kun
Dr Cheryl Lim
Dr Cinnie Yentia Soekojo
Dr Clarice Choong
Dr Lui Pak Ling
Dr Winnie Teo
Dr Eunice Lai

Leukaemia, Myelodysplastic and Myeloproliferative Neoplasms (MDS/MPN)

Haematology

Dr Melissa Ooi (Lead)
A/Prof Koh Liang Piu
Dr Esther Chan
Dr Tan Lip Kun
Dr Clarice Choong
Dr Lui Pak Ling
Dr Winnie Teo
Dr Song Yang
Dr Victor Ling

All Blood Cancers and Blood Disorders Programmes:

Radiology

Adj A/Prof Arvind Sinha
Dr Kok Tian Yue
Dr Loi Hoi Yin
Dr Syed Zama Ali
Dr Cherie Ng Wei Qi
Dr Ngam Pei Ing
Dr Ethanyin Lim

Brain and Spine Cancers

Chair

Adj A/Prof Bala Vellayappan

Neurosurgery

Clin A/Prof Low Shiong Wen
Clin A/Prof Yeo Tseng Tsai
Adj A/Prof Ira Sun
Adj A/Prof Vincent Nga
Dr Goh Chun Peng
Dr Nagarjun Boleam
Dr Nivedh Dinesh
Dr Aaron Foo
Dr Adriel Leong
Dr Colin Teo
Dr Swati Jain
Dr Tan Chin Lik

Medical Oncology

Adj A/Prof Andrea Wong
Dr Yvonne Ang

Radiation Oncology

Adj A/Prof Bala Vellayappan
Adj A/Prof Koh Wee Yao
Dr David Chia

Dr Lee Shing Fung

Paediatric Oncology

Dr Miriam Kimpo

Pathology

Dr Wu Bing Cheng

Radiology

Dr Andrew Makmur
Dr Clement Yong
Dr Goh Poh Sun
Dr Jocelyn Wong
Dr Tan Ai Peng
Dr Betsy Soon
Dr Kee Chee Kwang
Dr Low Xi Zhen
Dr Wu Peng

Breast Cancer

Chair

Adj A/Prof Samuel Ow

Surgical Oncology

Clin A/Prof Philip Iau
A/Prof Mikael Hartman
Adj A/Prof Oh Han Boon
Dr Choong Wen Ling
Dr Shaik Buhari
Dr Leong Wei Qi
Dr Lui Su Ann
Dr Serene Goh

Medical Oncology

E/Prof John Wong
Prof Lee Soo Chin
Adj A/Prof Andrea Wong
Adj A/Prof Lim Siew Eng
Adj A/Prof Samuel Ow
Dr Matilda Lee
Dr Rachel Wong

Radiation Oncology

Adj A/Prof Koh Wee Yao
Dr Leong Yiat Horng
Dr Ooi Kiat Huat

Pathology

A/Prof Thomas Putti
Dr Lau Kah Weng
Dr Gideon Tan
Dr Nicholas Tan

Radiology

A/Prof Quek Swee Tian
Dr Daniel Chee
Dr Felicity Pool
Dr Goh Yonggeng
Dr Joey Beh
Dr Lesley Goh
Dr Pooja Jagmohan
Dr Premilla Pillay
Dr Teh Hui Seong
Dr Edward Seah
Dr Eric Fang

Dr Nicola Lee
Dr James Yang

Plastic, Reconstructive & Aesthetic Surgery

Dr Jane Lim
Dr Janet Hung
Dr Vigneswaran Nallathamby
Dr Yap Yan Lin
Dr Low O Wern
Dr Priya Tiwari

Colorectal Cancer

Chair

Adj A/Prof Bettina Lieske

Deputy Chair

Dr Gloria Chan

Surgical Oncology

A/Prof Tan Ker Kan
Adj A/Prof Bettina Lieske
Adj A/Prof Cheong Wai Kit
Adj A/Prof Ian Tan
Dr Christopher Keh
Dr Seow Choon Sheong
Dr Bryan Buan
Dr Dedrick Chan
Dr Edwin Yang
Dr Heidi Chang
Dr Jarrod Tan
Dr Kwek Liling
Dr Lee Kai Yin
Dr Norman Lin

Medical Oncology

Adj A/Prof Chee Cheng Ean
Dr Yong Wei Peng
Dr Gloria Chan
Dr Ho Jingshan
Dr Joan Choo
Dr Robert Walsh
Dr Silvana Talisa Wijaya

Radiation Oncology

Adj A/Prof Bala Vellayappan
Adj A/Prof Jeremy Tey
Dr Lee Shing Fung
Dr Soon Yu Yang
Dr Tan Teng Hwee
Dr Elizabeth Chuk

Pathology

Prof Teh Ming
Dr Gwyneth Soon
Dr Jeffrey Lum
Dr Ooi Li Yin

Radiology

Adj A/Prof Bertrand Ang
Dr Amanda Cheng
Dr Koh Huiliang
Dr Lim Mei Chin
Dr Thian Yee Liang
Dr Low Ying Liang
Dr Samuel Lau

Genitourinary Cancer

Chair

A/Prof Edmund Chiong

Urology

Prof Kesavan Esuvaranathan
A/Prof Edmund Chiong
A/Prof Tiong Ho Yee
Adj A/Prof Benjamin Goh
Adj A/Prof Chua Wei Jin
Dr David T Consigliere
Dr Arshvin Kesavan
Dr Lu Jirong
Dr Tsang Woon Chau
Dr Wang Ziting
Dr Terence Law

Medical Oncology

Adj A/Prof Alvin Wong
Dr Natalie Ngoi
Dr Jerold Loh

Radiation Oncology

Adj A/Prof Jeremy Tey
Dr Ooi Kiat Huat
Dr David Chia

Pathology

Dr Thomas Thamboo
Dr Tan Hui Min

Radiology

Dr Bertrand Ang
Dr Thian Yee Liang
Dr Wynne Chua
Dr Cherie Ng Wei Qi
Dr Koh Huiliang
Dr Lim Mei Chin
Dr Low Ying Liang
Dr Ngam Pei Ing
Dr Ong Hanyang

Geriatric

Haematology-Oncology

Haematology

Dr Melissa Ooi [Lead]
Dr Clarice Choong

Radiation Oncology

Adj A/Prof Francis Ho [Lead]
Dr Elizabeth Chuk

Medical Oncology

Dr Nesaretnam Barr
Kumarakulasinghe
Dr Low Jia Li

Geriatrics

Dr Matthew Chen
Dr Nydia Camelia Rais
Dr Alexa Lai

Gynaecologic Cancer

Chair

Dr Joseph Ng

Gynaecologic Oncology

A/Prof Jeffrey Low
Dr Joseph Ng
Dr Pearl Tong
Dr Abhiram Kanneganti
Dr Grace Chan
Dr Jeslyn Wong
Dr Lim Li Min
Dr Yim Ga Won
Dr Bhadriraju Poornima

Medical Oncology

A/Prof David Tan
Adj A/Prof Lim Siew Eng
Dr Natalie Ngoi

Radiation Oncology

Dr Leong Yiat Horng
Dr Vicky Koh
Dr Michelle Tseng
Dr Elizabeth Chuk

Pathology

Dr Gideon Tan
Dr Tan Hui Min

Radiology

Adj A/Prof Bertrand Ang
Dr Thian Yee Liang
Dr Wynne Chua
Dr Wong Ying Mei

Head, Neck and Thyroid Cancers

Chair

A/Prof Raymond Tsang

Surgical Oncology

Prof Thomas Loh
A/Prof Raymond Tsang
Adj A/Prof Ng Li Shia
Dr Donovan Eu
Dr Joshua Tay
Dr Charmaine Tan
Dr Lim Wei Sian
Dr Yohanes Ting

Medical Oncology

Prof Goh Boon Cher
Dr Chong Wan Qin
Dr Low Jia Li

Radiation Oncology

Adj A/Prof Francis Ho
Dr Leong Yiat Horng
Dr Wong Lea Choung

Dr Tan Teng Hwee
Dr Yip Pui Lam

Pathology

A/Prof Fredrik Petersson
Dr Oon Ming Liang
Dr Wu Bingcheng
Dr Jaslyn Lee

Radiology

Dr Clement Yong
Dr Betsy Soon

General Surgery

Adj Prof Ngiam Kee Yuan
Dr Rajeev Parameswaran

Endocrinology

Dr Chionh Siok Bee
Dr Kathleen Sek
Dr Samantha Yang

Oral & Maxillofacial Surgery

A/Prof Zheng Lei
Dr John Loh

Plastic, Reconstructive & Aesthetic Surgery

Dr Jane Lim
Dr Yap Yan Lin

Hepato-Pancreato- Biliary (HPB) Cancer

Chair

Adj A/Prof Daniel Huang

Deputy Chair

Dr Nigel Tan

Surgical Oncology

A/Prof Alfred Kow
Adj A/Prof Gao Yujia
Dr Tan Ming Yuan
Dr Nigel Tan
Dr Pang Ning Qi
Dr Law Jia Hao

Medical Oncology

Adj A/Prof Chee Cheng Ean
Dr Yong Wei Peng
Dr Gloria Chan
Dr Ho Jingshan
Dr Joan Choo
Dr Robert Walsh
Dr Silvana Talisa Wijaya

Radiation Oncology

Adj A/Prof Bala Vellayappan
Adj A/Prof Francis Ho

Pathology

Prof Aileen Wee
Dr Gwyneth Soon
Dr Ooi Li Yin
Dr Ruoyu Shi

Radiology

Dr Lim Mei Chin

Interventional Radiology

A/Prof Raymond Liu
Dr Jimmy Kyaw Tun
Dr Kamarjit Singh Mangat
Dr Ong Shao Jin
Dr Pavel Singh
Dr Rahul Lohan
Dr Sundeep Punamiya

Hepatology

Prof Lim Seng Gee
Prof Kunda Rastislav
Prof Lawrence Ho
Adj Prof Mark Dhinesh Muthiah
A/Prof Dan Yock Young
Adj A/Prof Daniel Huang
Adj A/Prof Jonathan Lee
Adj A/Prof Lee Guan Huei
Adj A/Prof Low How Cheng
Dr Kenneth Koo
Dr Lee Yin Mei
Dr Sarah Low
Dr Sebastian Leong
Dr Wong Guan Wee
Dr Eunice Tan
Dr Koo Chieh Sian
Dr Kristie Fan
Dr Margaret Teng
Dr Lee Shi Yan
Dr Tan Yong Chuan

Lung/ Thoracic Cancer

Chair

Prof John Tam

Cardiac, Thoracic & Vascular Surgery

Prof John Tam
Dr Ooi Oon Cheong
Dr Jianye Chen
Dr Li Yue
Dr Lowell Leow
Dr Hari Kumar

Medical Oncology

Prof Goh Boon Cher
Dr Huang Yiqing
Dr Ross Soo
Dr Low Jia Li
Dr Yvonne Ang
Dr Kenneth Sooi

Radiation Oncology

Adj A/Prof Koh Wee Yao
Adj A/Prof Leong Cheng Nang
Dr Soon Yu Yang
Dr Lee Chia Ching

Pathology

Dr Seet Ju Ee
Dr Jeffrey Lum
Dr Lau Kah Weng

Radiology

Adj A/Prof Arvind Sinha
Adj A/Prof Lynette Teo

Dr Kok Tian Yue
Dr Loi Hoi Yin
Dr Ong Ching Ching
Dr Syed Zama Ali
Dr Cherie Ng Wei Qi
Dr Choo Yun Song
Dr Low Ying Liang
Dr Ngam Pei Ing
Dr Ethany Lim
Dr Lau Wai Keat

Interventional Radiology

Dr Dominic Fong

Respiratory and Critical Care Medicine

Adj A/Prof Adrian Kee
Adj A/Prof See Kay Choong
Dr Khoo Kay Leong
Dr Chan Hiang Ping
Dr Jeffrey Ng
Dr Mamta Ruparel

Musculoskeletal Cancer/ Sarcoma

Chair

Dr Anand D Jeyasekharan

Surgical Oncology

Adj Prof Mark Puhaindran
Adj A/Prof Cheong Wai Kit
Dr Chan Chung Ming
Dr Jonathan Tan
Dr Kumaran Rasappan
Dr Liang Zhen Chang

Medical Oncology

Dr Anand D Jeyasekharan
Dr Matilda Lee

Paediatric

Haematology-Oncology

Prof Allen Yeoh
Dr Bernice Oh
Dr Miriam Kimpo

Radiation Oncology

Dr Ooi Kiat Huat
Dr Timothy Cheo
Dr Tan Teng Hwee

Pathology

Prof Victor Lee
Dr Susan Hue
Dr Mok Ying Ting

Radiology

A/Prof Quek Swee Tian
Dr Agrawal Sachin
Dr Eide Sterling Ellis
Dr James Hallinan
Dr Loi Hoi Yin
Dr Singbal Salil Babla
Dr Sinha Arvind Kumar
Dr Syed Zama Ali
Dr Ting Yong Han
Dr Faimee Erwan
Dr Ge Shuliang
Dr Tan Loon Ying

Dr Tan Wei Chuan
Dr Tan Yi Liang

Paediatric Haematology-Oncology

Chair

Prof Allen Yeoh

Paediatric Surgical Oncology

Adj A/Prof Vidyadhar Mali
Dr Dale Loh
Dr Lee Yang Yang

Surgical Oncology

Adj A/Prof Vincent Nga
Dr Chan Chung Ming
Dr Aaron Foo

Paediatric Haematology- Oncology

E/Prof Quah Thuan Chong
Prof Allen Yeoh
Dr Bernice Oh
Dr Frances Yeap
Dr Miriam Kimpo
Dr Shawn Lee
Dr Jann Sy
Dr Krista Francisco

Radiation Oncology

Adj A/Prof Bala Vellayappan
Dr Vicky Koh
Dr Caryn Wujanto

Pathology

Adj A/Prof Derrick Lian

Radiology

Prof Khong Pek Lan
Dr Jeevesh Kapur
Dr Jonathan Sng
Dr Shabana Rasheed
Dr Teo Yi-Ming
Dr Betsy Soon

Ophthalmology (Retinoblastoma)

Adj A/Prof Gangadhara Sundar

Skin Cancer

Chair

A/Prof Peter Goon

Surgical Oncology

Prof Thomas Loh
Adj Prof Mark Puhaindran
Adj A/Prof Ng Li Shia
Adj A/Prof Raymond Tsang
Dr Chan Chung Ming
Dr Donovan Eu

Medical Oncology

Dr Chong Wan Qin

Radiation Oncology

Dr Tan Teng Hwee

Pathology

A/Prof Tan Kong Bing
Dr Justin Wong

Radiology

Dr Cherie Ng Wei Qi

Dermatology

A/Prof Nisha Suyien Chandran
A/Prof Peter Goon
Dr Chris Tan
Dr Adeline Yong
Dr Liao Mei Qi May
Dr Ooi Xue Ting

Plastic, Reconstructive & Aesthetic Surgery

A/Prof Lim Thiam Chye
Dr Jane Lim
Dr Lee Hanjing
Dr Yap Yan Lin

Upper Gastrointestinal Cancer

Chair

Dr Yong Wei Peng

Surgical Oncology

Prof Jimmy So
A/Prof Asim Shabbir
Dr Aung Lwin
Dr Cheong Chern Yuen
Dr Daryl Chia
Dr Teh Jun Liang

Medical Oncology

Dr Yong Wei Peng
Adj A/Prof Chee Cheng Ean
Dr Gloria Chan
Dr Ho Jingshan
Dr Joan Choo
Dr Robert Walsh
Dr Silvana Talisa Wijaya

Radiation Oncology

Adj A/Prof Bala Vellayappan
Adj A/Prof Francis Ho
Adj A/Prof Jeremy Tey
Dr Lee Shing Fung
Dr Soon Yu Yang
Dr Tan Teng Hwee
Dr Elizabeth Chuk

Pathology

Prof Teh Ming
Dr Gwyneth Soon
Dr Jeffrey Lum
Dr Ooi Li Yin

Radiology

Dr Amanda Cheng
Dr Koh Huiliang
Dr Lim Mei Chin
Dr Low Ying Liang

Gastroenterology

Prof Lawrence Ho
Adj A/Prof Jonathan Lee
Dr Koo Chieh Sian

Immune-Related Toxicity (IrTox)

Lead

Dr Huang Yiqing

Co-Leads

Adj A/Prof Alvin Wong
Adj A/Prof Frank Tay

Cardiology

Dr Tan Li Ling
Dr Christopher Koo

Dematology

Dr Chris Tan
Dr Nisha Chandran

Endocrine

Dr Samantha Yang

Gastroenterology

Dr Jonathan Lee

Haematology

Dr Esther Chan
Dr Yap Eng Soo
Dr Edwin Thong

Hepatology

Dr Mark Muthiah
Dr Margaret Teng

Medical Oncology

Dr Alvin Wong
Dr Huang Yiqing
Dr Joan Choo

Nephrology

Dr Chua Horng Ruey
Dr Martin Lee
Dr Da Yi

Neurology

Dr Amy Quek
Dr Chan Yee Cheun
Dr Kay Ng Wei Ping
Dr Quak Zhi Xuan

Ophthalmology

Dr Dawn Lim
Dr Yuen Yew Sen

Pulmonology

Dr Adrian Kee
Dr Valencia Lim
Dr Mamta Ruparel
Dr Gao Mingqi

Rheumatology

Dr Frank Tay
Dr Manjari
Dr Tang May Shuen

SPARK